Tesamorelin: Dosing Protocols

Dosing Information#

Tesamorelin (Egrifta/Egrifta SV) is an FDA-approved medication with an established dosing regimen based on Phase 3 clinical trial data. Unlike many investigational peptides, tesamorelin has formal prescribing information approved by the FDA that defines dose, route, frequency, and administration technique. The information below is derived from the approved prescribing information and published clinical trial protocols.

FDA-Approved Dosing Regimen#

Dose and Frequency#

The FDA-approved dose of tesamorelin is 2 mg administered by subcutaneous injection once daily. This dose was established through the Phase 3 clinical development program and was used in both pivotal trials that demonstrated significant visceral adipose tissue reduction in HIV-infected patients with lipodystrophy.

The 2 mg dose was selected based on Phase 2 dose-ranging studies that evaluated multiple dose levels. The 2 mg once-daily regimen provided an optimal balance of efficacy (clinically meaningful VAT reduction), safety (acceptable adverse event profile), and practicality (once-daily dosing).

Injection Site#

Tesamorelin must be injected subcutaneously into the abdomen. The prescribing information specifies that the injection should be administered in the abdominal area, rotating sites to reduce the risk of injection site reactions and localized lipodystrophy. Patients should avoid injecting into scar tissue, bruised areas, or areas that are red or irritated.

The choice of abdominal injection is relevant given that the approved indication is reduction of abdominal visceral fat. While the systemic nature of GH stimulation means that the injection site does not determine where fat loss occurs, the abdomen was the standardized site used in clinical trials and is specified in the approved labeling.

Duration of Treatment#

There is no defined maximum treatment duration for tesamorelin. Clinical trial data support efficacy through 52 weeks of continuous treatment. However, extension studies demonstrated that discontinuation of tesamorelin leads to reaccumulation of visceral adipose tissue within weeks to months, indicating that ongoing treatment is necessary to maintain therapeutic benefit.

The prescribing information recommends that clinicians periodically reassess the need for continued treatment. Factors to consider include:

• Whether VAT reduction goals have been achieved and maintained
• Patient tolerance and adherence
• Monitoring of IGF-1 levels (discontinuation should be considered if IGF-1 is persistently elevated above the age-adjusted normal range)
• Glucose metabolism status (particularly in patients developing glucose intolerance)

Reconstitution and Preparation#

Original Egrifta Formulation#

The original Egrifta formulation is supplied as a lyophilized powder in a single-use vial. Each vial contains 1 mg of tesamorelin; therefore, two vials are required for the full 2 mg daily dose. Reconstitution steps:

1. Remove one vial of tesamorelin and one syringe of sterile water for injection from the refrigerator (if stored cold) or kit
2. Using the provided syringe, inject the sterile water for injection into the tesamorelin vial
3. Roll the vial gently between the palms for approximately 30 seconds to dissolve the powder
4. Do not shake the vial, as this can cause denaturation and foaming
5. Inspect the solution visually; it should be clear and colorless to slightly yellow with no visible particles
6. Withdraw the reconstituted solution and repeat with the second vial using a new syringe and vial of diluent
7. Combine both reconstituted doses into a single syringe for injection

Egrifta SV (Reformulated)#

Egrifta SV was approved by the FDA in 2020 as a reformulated version designed for improved convenience. Key differences from the original formulation:

• Each vial contains the full 2 mg dose (single vial required per daily dose)
• Smaller reconstitution volume with a pre-filled diluent syringe
• Reduced total injection volume
• Equivalent clinical pharmacology and efficacy to the original formulation

Reconstitution of Egrifta SV follows the same general principles: inject the provided diluent into the vial, roll gently to dissolve, inspect for clarity, and withdraw the full dose for injection.

Administration Technique#

1. Select an injection site on the abdomen, avoiding the navel and any areas of scarring, bruising, redness, or irritation
2. Clean the injection site with an alcohol swab
3. Pinch a fold of skin and insert the needle at a 45-90 degree angle (depending on subcutaneous tissue depth)
4. Inject the solution slowly
5. Withdraw the needle and apply gentle pressure with a clean cotton ball or gauze
6. Dispose of used needles and syringes in a sharps container

Injection Site Rotation#

Rotate injection sites within the abdominal area with each daily injection. A systematic rotation pattern (such as dividing the abdomen into quadrants and rotating clockwise) can help ensure that the same site is not used on consecutive days. Proper rotation helps minimize:

• Injection site reactions (erythema, induration, pruritus)
• Local tissue fibrosis
• Lipodystrophic changes at injection sites

Storage Guidelines#

Clinical Trial Dosing Protocols#

Pivotal Phase 3 Trials (HIV Lipodystrophy)#

In both pivotal trials, HIV-infected patients with excess abdominal fat were randomized to receive tesamorelin 2 mg or placebo by daily subcutaneous abdominal injection for 26 weeks. Key protocol elements included:

• Patients were trained on self-injection technique at study enrollment
• Compliance was monitored through drug accountability (returned vials) and patient diaries
• IGF-1 levels were monitored at baseline and periodically throughout the study
• Fasting glucose and lipid panels were assessed at regular intervals
• Trunk fat was measured by DEXA scan, and visceral adipose tissue was measured by CT at the L4-L5 level

Extension Studies#

Patients who completed the initial 26-week treatment period were eligible for extension studies of an additional 26 weeks. In the extension phase, patients originally on tesamorelin could continue treatment, while patients originally on placebo were re-randomized to tesamorelin or placebo. This design allowed assessment of durability of response with continued treatment and evaluation of the effects of treatment withdrawal.

GILT Trial (NASH/Hepatic Steatosis)#

The GILT trial investigated tesamorelin for hepatic steatosis in HIV-infected patients using the same 2 mg daily subcutaneous dose for 12 months. This longer treatment duration provided additional safety and efficacy data. The primary endpoint was change in hepatic fat fraction measured by magnetic resonance spectroscopy. Liver biopsies were performed in a subset of patients to assess histological changes.

Monitoring Recommendations#

The following monitoring parameters are recommended for patients receiving tesamorelin based on the prescribing information and clinical trial experience:

• IGF-1 levels: Monitor at baseline and periodically during treatment. Consider discontinuation if IGF-1 is persistently elevated above the upper limit of age-adjusted normal
• Fasting glucose and HbA1c: Monitor at baseline and periodically, particularly in patients with diabetes, pre-diabetes, or risk factors for glucose intolerance
• Lipid panel: Assess at baseline and periodically
• Body composition: Clinical assessment of abdominal fat and optionally DEXA or CT imaging to evaluate treatment response
• Pregnancy testing: Women of childbearing potential should have a negative pregnancy test before initiating treatment
• Injection site assessment: Monitor for injection site reactions, local lipodystrophy, or signs of infection

Evidence Gaps#

• Dose-response data from Phase 2 studies are limited in the published literature; optimal doses for non-lipodystrophy indications are not established
• Whether lower doses might provide partial efficacy with reduced metabolic side effects has not been published
• Dosing adjustments for renal or hepatic impairment have not been formally studied
• Pediatric dosing has not been established (tesamorelin is approved only for adults)
• Combination dosing with GH secretagogues or other metabolic agents has not been evaluated in controlled trials

Related Reading#

• Tesamorelin overview and research guide
• Tesamorelin side effects profile
• Tesamorelin research evidence